BRIEF-Mural Oncology Announces Publication Highlighting Promising Clinical Antitumor Activity Shown In Its Artistry-1 Clinical Trial Of Nemvaleukin

Reuters11-21

BRIEF-<a href="https://laohu8.com/S/MURA">Mural Oncology</a> Announces Publication Highlighting Promising Clinical Antitumor Activity Shown In Its Artistry-1 Clinical Trial Of Nemvaleukin

Nov 20 (Reuters) - Mural Oncology PLC MURA.O:

MURAL ONCOLOGY ANNOUNCES PUBLICATION HIGHLIGHTING PROMISING CLINICAL ANTITUMOR ACTIVITY SHOWN IN ITS ARTISTRY-1 CLINICAL TRIAL OF NEMVALEUKIN, ITS LEAD ENGINEERED FUSION PROTEIN, IN THE JOURNAL FOR IMMUNOTHERAPY OF CANCER

Source text: ID:nGNX1c1yP2

Further company coverage: MURA.O

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2485174981?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-21 06:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2485174981","market":"us","top_or_hot":-1,"title":"BRIEF-Mural Oncology Announces Publication Highlighting Promising Clinical Antitumor Activity Shown In Its Artistry-1 Clinical Trial Of Nemvaleukin","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/MURA\">Mural Oncology</a> Announces Publication Highlighting Promising Clinical Antitumor Activity Shown In Its Artistry-1 Clinical Trial Of Nemvaleukin</title></head><body><p><span>Nov 20 (Reuters)</span><span> - </span>Mural Oncology <a href=\"https://laohu8.com/S/PLC\">PLC</a> <span>MURA.O</span>:</p><ul><li><p>MURAL ONCOLOGY ANNOUNCES PUBLICATION HIGHLIGHTING PROMISING CLINICAL ANTITUMOR ACTIVITY SHOWN IN ITS ARTISTRY-1 CLINICAL TRIAL OF NEMVALEUKIN, ITS LEAD ENGINEERED FUSION PROTEIN, IN THE JOURNAL FOR IMMUNOTHERAPY OF CANCER</p></li></ul><p>Source text: <span>ID:nGNX1c1yP2</span></p><p>Further company coverage: <span>MURA.O</span></p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Mural Oncology Announces Publication Highlighting Promising Clinical Antitumor Activity Shown In Its Artistry-1 Clinical Trial Of Nemvaleukin</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Mural Oncology Announces Publication Highlighting Promising Clinical Antitumor Activity Shown In Its Artistry-1 Clinical Trial Of Nemvaleukin\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-21 06:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241120:nTUABR6QBJ:1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BRIEF-Mural Oncology Announces Publication Highlighting Promising Clinical Antitumor Activity Shown In Its Artistry-1 Clinical Trial Of NemvaleukinNov 20 (Reuters) - Mural Oncology PLC MURA.O:MURAL ...</p>\n\n<a href=\"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241120:nTUABR6QBJ:1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241120:nTUABR6QBJ:1","article_id":"2485174981","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2485174981","pubTimestamp":1732141317,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Mural Oncology Announces Publication Highlighting Promising Clinical Antitumor Activity Shown In Its Artistry-1 Clinical Trial Of NemvaleukinNov 20 (Reuters) - Mural Oncology PLC MURA.O:MURAL ON","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","MURA":"Mural Oncology"},"translate_title":"BRIEF-Mural Oncology宣布发表文章，强调其Nemvaleukin的Artistry-1临床试验中显示出有希望的临床抗肿瘤活性","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MURA":0.9},"content_text":"BRIEF-Mural Oncology Announces Publication Highlighting Promising Clinical Antitumor Activity Shown In Its Artistry-1 Clinical Trial Of NemvaleukinNov 20 (Reuters) - Mural Oncology PLC MURA.O:MURAL ONCOLOGY ANNOUNCES PUBLICATION HIGHLIGHTING PROMISING CLINICAL ANTITUMOR ACTIVITY SHOWN IN ITS ARTISTRY-1 CLINICAL TRIAL OF NEMVALEUKIN, ITS LEAD ENGINEERED FUSION PROTEIN, IN THE JOURNAL FOR IMMUNOTHERAPY OF CANCERSource text: ID:nGNX1c1yP2Further company coverage: MURA.O","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2485174981"}